---
title: "Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/109478642.md"
description: "Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target."
datetime: "2024-03-07T19:01:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/109478642.md)
  - [en](https://longbridge.com/en/news/109478642.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/109478642.md)
---

# Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target

Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target.

### Related Stocks

- [PPBT.US](https://longbridge.com/en/quote/PPBT.US.md)

## Related News & Research

- [Purple Biotech announces annual shareholder meeting](https://longbridge.com/en/news/294256279.md)
- [Purple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy](https://longbridge.com/en/news/294257073.md)
- [Innovative ETF Strategies That Are Paying Off This Summer](https://longbridge.com/en/news/293944000.md)
- [FBT and IBB are not the same biotech bet, and 5 years of returns prove it](https://longbridge.com/en/news/293926015.md)
- [US High Growth Tech Stocks To Watch In July 2026](https://longbridge.com/en/news/294353486.md)